AbbVie Gets Orphan Drug Designation for Spinal Cord Injury Treatment
September 28 2020 - 9:29AM
Dow Jones News
By Chris Wack
AbbVie Inc. said Monday the U.S. Food and Drug Administration
has granted Orphan Drug and Fast Track designations for elezanumab
ABT-555, an investigational treatment for patients following spinal
cord injury.
The pharmaceutical company said its elezanumab is being
investigated to treat spinal cord injuries, multiple sclerosis and
acute ischemic stroke. It is currently in a phase 2 study for the
treatment of spinal cord injury.
AbbVie is currently partnering with the Shirley Ryan AbilityLab
in a pilot study involving 20 spinal cord injury patients. The
pilot study will inform the ongoing Phase 2 study of elezanumab by
testing optimal biosensor placement to capture surface
electromyography, among other assessments. The pilot study will be
completed in about two months.
AbbVie also is partnering with United Spinal Association and the
North American Spinal Cord Injury Consortium to support spinal cord
injury awareness and incorporate spinal cord injury community
perspectives into our clinical research and outreach.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 28, 2020 09:14 ET (13:14 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2023 to Apr 2024
